BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ho MC, Hasegawa K, Chen XP, Nagano H, Lee YJ, Chau GY, Zhou J, Wang CC, Choi YR, Poon RT, Kokudo N. Surgery for Intermediate and Advanced Hepatocellular Carcinoma: A Consensus Report from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014). Liver Cancer 2016;5:245-56. [PMID: 27781197 DOI: 10.1159/000449336] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Zhang ZQ, Xiong L, Zhou JJ, Miao XY, Li QL, Wen Y, Zou H. Ability of the ALBI grade to predict posthepatectomy liver failure and long-term survival after liver resection for different BCLC stages of HCC. World J Surg Oncol. 2018;16:208. [PMID: 30326907 DOI: 10.1186/s12957-018-1500-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
2 Matsukuma S, Sakamoto K, Tokuhisa Y, Tokumitsu Y, Matsui H, Kanekiyo S, Tomochika S, Iida M, Suzuki N, Takeda S, Ueno T, Wada H, Kobayashi S, Saeki I, Eguchi H, Sakon M, Sakaida I, Nagano H. Outcomes following liver resection for multinodular Barcelona Clinic Liver Cancer-B hepatocellular carcinoma. Oncol Lett 2018;16:6383-92. [PMID: 30344760 DOI: 10.3892/ol.2018.9420] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Zhou C, Peng Y, Zhou K, Zhang L, Zhang X, Yu L, Hu J, Chen F, Qiu S, Zhou J, Fan J, Ren Z, Wang Z. Surgical resection plus radiofrequency ablation for the treatment of multifocal hepatocellular carcinoma. Hepatobiliary Surg Nutr 2019;8:19-28. [PMID: 30881962 DOI: 10.21037/hbsn.2018.11.19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
4 Kokudo N, Kokudo T, Hasegawa K. Role of Liver Resection for Hepatocellular Carcinoma with Vascular Invasion: Emerging Evidence from Western Countries. Liver Cancer 2021;10:404-6. [PMID: 34721503 DOI: 10.1159/000517418] [Reference Citation Analysis]
5 Liang Y, Xu F, Wang Z, Tan C, Zhang N, Wei X, Jiang X, Wu H. A gadoxetic acid-enhanced MRI-based multivariable model using LI-RADS v2018 and other imaging features for preoperative prediction of macrotrabecular-massive hepatocellular carcinoma. Eur J Radiol 2022;153:110356. [PMID: 35623312 DOI: 10.1016/j.ejrad.2022.110356] [Reference Citation Analysis]
6 Hsiao P, Hsieh KC, Chen YS, Hsu CC, Lo GH, Li YC, Hsieh PM, Lin HY, Wu TC, Yeh JH, Lin CW. Sorafenib with concurrent multiple-line therapies improves overall survival in advanced stage hepatocellular carcinoma. Medicine (Baltimore) 2019;98:e16074. [PMID: 31232945 DOI: 10.1097/MD.0000000000016074] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
7 Xu QG, Yuan SX, Tao QF, Yu J, Cai J, Yang Y, Guo XG, Lin KY, Ma JZ, Dai DS, Wang ZG, Gu FM, Zhao LH, Li LQ, Liu JF, Sun SH, Zang YJ, Liu H, Yang F, Zhou WP. A novel HBx genotype serves as a preoperative predictor and fails to activate the JAK1/STATs pathway in hepatocellular carcinoma. J Hepatol 2019;70:904-17. [PMID: 30654066 DOI: 10.1016/j.jhep.2019.01.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
8 Fang KC, Kao WY, Su CW, Chen PC, Lee PC, Huang YH, Huo TI, Chang CC, Hou MC, Lin HC, Wu JC. The Prognosis of Single Large Hepatocellular Carcinoma Was Distinct from Barcelona Clinic Liver Cancer Stage A or B: The Role of Albumin-Bilirubin Grade. Liver Cancer. 2018;7:335-358. [PMID: 30488023 DOI: 10.1159/000487407] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
9 Zhao J, Xie Y. Progress in research of hepatocellular carcinoma with tumor thrombus. Shijie Huaren Xiaohua Zazhi 2019; 27(20): 1239-1247 [DOI: 10.11569/wcjd.v27.i20.1239] [Reference Citation Analysis]
10 Su Y, Liu Y, Hsiao C, Hsu C, Chen L. Trial Designs for Integrating Novel Therapeutics into the Management of Intermediate-Stage Hepatocellular Carcinoma. JHC 2022;Volume 9:517-36. [DOI: 10.2147/jhc.s220978] [Reference Citation Analysis]
11 He Y, Liang T, Mo S, Chen Z, Zhao S, Zhou X, Yan L, Wang X, Su H, Zhu G, Han C, Peng T. Effect of timing of surgical resection of primary hepatocellular carcinoma on survival outcomes in elderly patients and prediction of clinical models. BMC Gastroenterol 2021;21:230. [PMID: 34020603 DOI: 10.1186/s12876-021-01815-4] [Reference Citation Analysis]
12 Song Z, Yu Z, Chen L, Zhou Z, Zou Q, Liu Y. MicroRNA-1181 supports the growth of hepatocellular carcinoma by repressing AXIN1. Biomed Pharmacother 2019;119:109397. [PMID: 31514071 DOI: 10.1016/j.biopha.2019.109397] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
13 Allaire M, Goumard C, Lim C, Le Cleach A, Wagner M, Scatton O. New frontiers in liver resection for hepatocellular carcinoma. JHEP Rep. 2020;2:100134. [PMID: 32695968 DOI: 10.1016/j.jhepr.2020.100134] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
14 Lin CW, Chen YS, Lo GH, Wu TC, Yeh JH, Yeh ML, Dai CY, Huang JF, Chuang WL, Roberts L, Jun DW, Toyoda H, Yasuda S, Nguyen MH, Yu ML. Resubclassification and clinical management for Barcelona Clinic Liver Cancer Stage C hepatocellular carcinoma. Hepatol Int 2021;15:946-56. [PMID: 34008091 DOI: 10.1007/s12072-021-10169-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Iida H, Kaibori M, Hirokawa F, Inoue Y, Ueno M, Matsui K, Ishizaki M, Tanaka S, Takemura S, Nomi T, Hokutou D, Noda T, Eguchi H, Nakai T, Maehira H, Mori H, Tani M, Kubo S. New Hepatic Resection Criteria for Intermediate-Stage Hepatocellular Carcinoma Can Improve Long-Term Survival: A Retrospective, Multicenter Collaborative Study. Asian Pac J Cancer Prev 2020;21:2903-11. [PMID: 33112547 DOI: 10.31557/APJCP.2020.21.10.2903] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Lünse S, Heidecke C, Partecke LI; Department of General Surgery, Visceral, Thoracic and Vascular Surgery, Universitätsmedizin Greifswald, Greifswald, Germany, Department of General Surgery, Visceral, Thoracic and Vascular Surgery, Universitätsmedizin Greifswald, Greifswald, Germany, Department of General, Visceral and Thoracic Surgery, Helios Klinikum Schleswig, Schleswig, Germany. Current Topics and Perspectives in Surgical Management of Hepatocellular Carcinoma. In: Tirnitz-parker JE, editor. Hepatocellular Carcinoma. Codon Publications; 2019. pp. 111-25. [DOI: 10.15586/hepatocellularcarcinoma.2019.ch6] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
17 Fernandes ESM, Rodrigues PD, Álvares-da-Silva MR, Scaffaro LA, Farenzena M, Teixeira UF, Waechter FL. Treatment strategies for locally advanced hepatocellular carcinoma. Transl Gastroenterol Hepatol 2019;4:12. [PMID: 30976715 DOI: 10.21037/tgh.2019.01.02] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
18 Chen YS, Hsieh PM, Lin HY, Hung CM, Lo GH, Hsu YC, Lu IC, Lee CY, Wu TC, Yeh JH, Hsiao P, Li YC, Wang YC, Hsieh KC, Lin CW. Surgical resection significantly promotes the overall survival of patients with hepatocellular carcinoma: a propensity score matching analysis. BMC Gastroenterol 2021;21:220. [PMID: 33990184 DOI: 10.1186/s12876-021-01807-4] [Reference Citation Analysis]
19 Yang J, Tao HS, Cai W, Zhu W, Zhao D, Hu HY, Liu J, Fang CH. Accuracy of actual resected liver volume in anatomical liver resections guided by 3-dimensional parenchymal staining using fusion indocyanine green fluorescence imaging. J Surg Oncol 2018;118:1081-7. [PMID: 30293249 DOI: 10.1002/jso.25258] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
20 Chen KY, Huang YH, Teo WH, Chang CW, Chen YS, Yeh YC, Lee CJ, Lo JF. Loss of Tid1/DNAJA3 Co-Chaperone Promotes Progression and Recurrence of Hepatocellular Carcinoma after Surgical Resection: A Novel Model to Stratify Risk of Recurrence. Cancers (Basel) 2021;13:E138. [PMID: 33406664 DOI: 10.3390/cancers13010138] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Abou-alfa GK, Jarnagin W, El Dika I, D'angelica M, Lowery M, Brown K, Ludwig E, Kemeny N, Covey A, Crane CH, Harding J, Shia J, O'reilly EM. Liver and Bile Duct Cancer. Abeloff's Clinical Oncology. Elsevier; 2020. pp. 1314-1341.e11. [DOI: 10.1016/b978-0-323-47674-4.00077-3] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Zheng Y, Wang K, Zhou J, Zhang Z, Xiong L, Wen Y, Zou H. Portal hypertension predicts short-term and long-term outcomes after hepatectomy in hepatocellular carcinoma patients. Scandinavian Journal of Gastroenterology 2018;53:1562-8. [DOI: 10.1080/00365521.2018.1538386] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
23 Kong J, Shen S, Wang W. Synchronous hepatectomy and splenectomy vs hepatectomy for selected patients with hepatocellular carcinoma and clinically significant portal hypertension: A systematic review and meta-analysis. J Surg Oncol 2019;119:964-73. [PMID: 30775785 DOI: 10.1002/jso.25392] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
24 Kabir T, Syn N, Ramkumar M, Yeo EYJ, Teo JY, Koh YX, Lee SY, Cheow PC, Chow PKH, Chung AYF, Ooi LL, Chan CY, Goh BKP. Effect of surgical delay on survival outcomes in patients undergoing curative resection for primary hepatocellular carcinoma: Inverse probability of treatment weighting using propensity scores and propensity score adjustment. Surgery 2020;167:417-24. [PMID: 31677800 DOI: 10.1016/j.surg.2019.09.022] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
25 Ye JZ, Wang YY, Bai T, Chen J, Xiang BD, Wu FX, Li LQ. Surgical resection for hepatocellular carcinoma with portal vein tumor thrombus in the Asia-Pacific region beyond the Barcelona Clinic Liver Cancer treatment algorithms: a review and update. Oncotarget. 2017;8:93258-93278. [PMID: 29190996 DOI: 10.18632/oncotarget.18735] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
26 Wang Y, Sun H, Xiao Z, Zhang D, Bao X, Wei N. XWL-1-48 exerts antitumor activity via targeting topoisomerase II and enhancing degradation of Mdm2 in human hepatocellular carcinoma. Sci Rep 2017;7:9989. [PMID: 28855652 DOI: 10.1038/s41598-017-10577-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
27 Zhong JH, Torzilli G, Xing H, Li C, Han J, Liang L, Zhang H, Dai SY, Li LQ, Shen F, Yang T. Controversies and evidence of hepatic resection for hepatocellular carcinoma. BBA Clin. 2016;6:125-130. [PMID: 27761414 DOI: 10.1016/j.bbacli.2016.10.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
28 Peng SY, Wang XA, Huang CY, Li JT, Hong DF, Wang YF, Xu B. Better surgical treatment method for hepatocellular carcinoma with portal vein tumor thrombus. World J Gastroenterol 2018; 24(40): 4527-4535 [PMID: 30386102 DOI: 10.3748/wjg.v24.i40.4527] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
29 Lin CW, Chen YS, Lo GH, Hsu YC, Hsu CC, Wu TC, Yeh JH, Hsiao P, Hsieh PM, Lin HY, Shu CW, Hung CM. Comparison of overall survival on surgical resection versus transarterial chemoembolization with or without radiofrequency ablation in intermediate stage hepatocellular carcinoma: a propensity score matching analysis. BMC Gastroenterol 2020;20:99. [PMID: 32272898 DOI: 10.1186/s12876-020-01235-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Su YY, Li CC, Lin YJ, Hsu C. Adjuvant versus Neoadjuvant Immunotherapy for Hepatocellular Carcinoma: Clinical and Immunologic Perspectives. Semin Liver Dis 2021;41:263-76. [PMID: 34130338 DOI: 10.1055/s-0041-1730949] [Reference Citation Analysis]
31 Hyun MH, Lee YS, Kim JH, Lee CU, Jung YK, Seo YS, Yim HJ, Yeon JE, Byun KS. Hepatic resection compared to chemoembolization in intermediate- to advanced-stage hepatocellular carcinoma: A meta-analysis of high-quality studies. Hepatology 2018;68:977-93. [PMID: 29543988 DOI: 10.1002/hep.29883] [Cited by in Crossref: 84] [Cited by in F6Publishing: 84] [Article Influence: 21.0] [Reference Citation Analysis]
32 Xie DY, Ren ZG, Zhou J, Fan J, Gao Q. Critical appraisal of Chinese 2017 guideline on the management of hepatocellular carcinoma. Hepatobiliary Surg Nutr. 2017;6:387-396. [PMID: 29312973 DOI: 10.21037/hbsn.2017.11.01] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 6.2] [Reference Citation Analysis]
33 Gunasekaran G, Bekki Y, Lourdusamy V, Schwartz M. Surgical Treatments of Hepatobiliary Cancers. Hepatology 2021;73 Suppl 1:128-36. [PMID: 32438491 DOI: 10.1002/hep.31325] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 29.0] [Reference Citation Analysis]
34 Zhong JH, Peng NF, You XM, Ma L, Xiang X, Wang YY, Gong WF, Wu FX, Xiang BD, Li LQ. Tumor stage and primary treatment of hepatocellular carcinoma at a large tertiary hospital in China: A real-world study. Oncotarget 2017;8:18296-302. [PMID: 28407686 DOI: 10.18632/oncotarget.15433] [Cited by in Crossref: 23] [Cited by in F6Publishing: 29] [Article Influence: 4.6] [Reference Citation Analysis]
35 Yang J, Yang J, Yan L, Wen T, Li B, Wang W. Hepatic resection vs. transarterial chemoembolization for hepatocellular carcinoma beyond the Milan criteria with portal hypertension. Digestive and Liver Disease 2018;50:713-9. [DOI: 10.1016/j.dld.2018.03.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
36 Lu L, Zheng P, Wu Z, Chen X. Hepatic Resection Versus Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: A Cohort Study. Front Oncol 2021;11:618937. [PMID: 34778022 DOI: 10.3389/fonc.2021.618937] [Reference Citation Analysis]
37 Khajeh E, Moghadam AD, Eslami P, Ali-hasan-al-saegh S, Ramouz A, Shafiei S, Ghamarnejad O, Dezfouli SA, Rupp C, Springfeld C, Carvalho C, Probst P, Mousavizadeh SM, Mehrabi A. Statin use is associated with the reduction in hepatocellular carcinoma recurrence after liver surgery. BMC Cancer 2022;22. [DOI: 10.1186/s12885-022-09192-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
38 Yang N, Chen J, Zhang H, Wang X, Yao H, Peng Y, Zhang W. LncRNA OIP5-AS1 loss-induced microRNA-410 accumulation regulates cell proliferation and apoptosis by targeting KLF10 via activating PTEN/PI3K/AKT pathway in multiple myeloma. Cell Death Dis. 2017;8:e2975. [PMID: 28796257 DOI: 10.1038/cddis.2017.358] [Cited by in Crossref: 91] [Cited by in F6Publishing: 97] [Article Influence: 18.2] [Reference Citation Analysis]
39 Chen LT, Martinelli E, Cheng AL, Pentheroudakis G, Qin S, Bhattacharyya GS, Ikeda M, Lim HY, Ho GF, Choo SP, Ren Z, Malhotra H, Ueno M, Ryoo BY, Kiang TC, Tai D, Vogel A, Cervantes A, Lu SN, Yen CJ, Huang YH, Chen SC, Hsu C, Shen YC, Tabernero J, Yen Y, Hsu CH, Yoshino T, Douillard JY. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Ann Oncol. 2020;31:334-351. [PMID: 32067677 DOI: 10.1016/j.annonc.2019.12.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
40 Famularo S, Giani A, Di Sandro S, Sandini M, Giacomoni A, Pinotti E, Lauterio A, Gianotti L, De Carlis L, Romano F. Does the Pringle maneuver affect survival and recurrence following surgical resection for hepatocellular carcinoma? A western series of 441 patients. J Surg Oncol 2018;117:198-206. [DOI: 10.1002/jso.24819] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
41 Lopez-Lopez V, Robles-Campos R, Brusadin R, Lopez-Conesa A, de la Peña J, Caballero A, Arevalo-Perez J, Navarro-Barrios A, Gómez P, Parrilla-Paricio P. ALPPS for hepatocarcinoma under cirrhosis: a feasible alternative to portal vein embolization. Ann Transl Med 2019;7:691. [PMID: 31930092 DOI: 10.21037/atm.2019.10.57] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
42 Du Z, Dong J, Bi J, Bai R, Zhang J, Wu Z, Lv Y, Zhang X, Wu R. Predictive value of the preoperative neutrophil-to-lymphocyte ratio for the development of hepatocellular carcinoma in HBV-associated cirrhotic patients after splenectomy. PLoS One. 2018;13:e0195336. [PMID: 29621282 DOI: 10.1371/journal.pone.0195336] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]